Comparison of losartan and carvedilol on attenuating inflammatory and oxidative response and preserving energy transcription factors and left ventricular function in dilated cardiomyopathy rats

International Heart Journal

Volumn 49, Issue 5, 2008, Pages 605-619

  Chua, Sarah ^a   Sheu, Jiunn Jye ^a   Chang, Li Teh ^b   Lee, Fan Yen ^a   Wu, Chiung Jen ^a   Sun, Cheuk Kwan ^a   Yip, Hon Kan ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b MEIHO UNIVERSITY   (Taiwan)

Author keywords

Dilated cardiomyopathy; Inflammation; Pharmacological modulation

Indexed keywords

CARVEDILOL; CONNEXIN 43; CYTOCHROME C; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN 1; GELATINASE B; INTERLEUKIN 10; LOSARTAN; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAZOLE DERIVATIVE; PROPANOLAMINE DERIVATIVE; TRANSCRIPTION FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; COMPARATIVE STUDY; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; GENE EXPRESSION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE CONTRACTILITY; HEART MUSCLE FIBROSIS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SPRAGUE DAWLEY RAT; ANIMAL; MALE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; CARBAZOLES; CARDIOMYOPATHY, DILATED; CONNEXIN 43; LOSARTAN; MALE; OXIDATIVE STRESS; PROPANOLAMINES; RATS; RATS, SPRAGUE-DAWLEY; TRANSCRIPTION FACTORS; VENTRICULAR FUNCTION, LEFT;

EID: 58149176611     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.49.605     Document Type: Article

References (31)

1. Manolio TA, Baughman KL, Rodeheffer R, et al. Prevalence and etiology of dilated cardiomyopathy (summary of a National Heart, Lung, and Blood Institute workshop). Am J Cardiol 1992; 69: 1458-66.
2. Deg GW, Fusier V. Idiopathic dilated cardiomyopathy. New Engl J Med 1994; 331: 1564-75. (Review)
3. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995; 273: 1450-6.
4. Blum A, Miller H. Role of cytokines in heart failure. Am Heart J 1998; 135: 181-6. (Review)
5. Suleiman M, Khatib R, Agmon Y, et al. Early inflammation and risk of long-term development of heart failure and mortality in survivors of acute myocardial infarction predictive role of C-reactive protein. J Am Coll Cardiol 2006; 47: 962-8.
6. Valgimigli M, Ceconi C, Malagutti P, et al. Tumor necrosis factor-alpha receptor 1 is a major predictor of mortality and new-onset heart failure in patients with acute myocardial infarction: the Cytokine-Activation and Long-Term Progrosis in Myocardial Infarction (C-ALPHA) study. Circulation 2005; 111: 863-70.
7. Neumann FJ, Ott I, Gawaz M, et al. Cardiac release of cytokines and inflammatory responses in acute myocardial infarction. Circulation 1995; 92: 748-55.
8. Ono K, Matsumori A, Shioi T, Furukawa Y, Sasayama S. Cytokine gene expression after myocardial infarction in rat hearts: possible implication in left ventricular remodeling. Circulation 1998; 98: 149-56.
9. Youssef AA, Chang LT, Hang CL, et al. Level and value of interleukin-18 in patients with acute myocardial infarction undergoing primary coronary angioplasty. Circ J 2007; 71: 703-8.
10. Garnier A, Fortin D, Deloménie C, Momken I, Veksler V, Ventura-Clapier R. Depressed mitochondrial transcription factors and oxidative capacity in rat failing cardiac and skeletal muscles. J Physiol 2003; 551: 491-501.
11. Chang LT, Sun CK, Wang CY, et al. Downregulation of peroxisme proliferator activated receptor gamma coactivator 1 alpha in diabetic rats. Int Heart J 2006; 47: 901-10.
12. Sun CK, Chang LT, Sheu JJ, et al. Losartan preserves integrity of cardiac gap junctions and PGC-1 alpha gene expression and prevents cellular apoptosis in remote area of left ventricular myocardium following acute myocardial infarction. Int Heart J 2007; 48: 533-46.
13. Kirchhoff S, Nelles E, Hagendorff A, Krüger O, Traub O, Willecke K. Reduced cardiac conduction velocity and predisposition to arrhythmias in connexin40-deficient mice. Curr Biol 1998; 8: 299-302.
14. Lerner DL, Yamada KA, Schuessler RB, Saffitz JE. Accelerated onset and increased incidence of ventricular arrhythmias induced by ischemia in Cx43-deficient mice. Circulation 2000; 101: 547-52.
15. Peters NS, Green CR, Poole-Wilson PA, Severs NJ. Cardiac arrhythmogenesis and the gap junction. J Mol Cell Cardiol 1995; 27: 37-44. (Review)
16. Singal PK, Khaper N, Palace V, Kumar D. The role of oxidative stress in the genesis of heart disease. Cardiovasc Res 1998; 40: 426-32. (Review)
17. Ide T, Tsutsui H, Kinugawa S, et al. Mitochondrial electron transport complex I is a potential source of oxygen free radicals in the failing myocardium. Circ Res 1999; 85: 357-63.
18. Ichihara S, Yamada Y, Ichihara G, et al. Attenuation of oxidative stress and cardiac dysfunction by bisoprolol in an animal model of dilated cardiomyopathy. Biochem Biophys Res Commun 2006; 350: 105-13.
19. Tsutamoto T, Wada A, Matsumoto T, et al. Relationship between tumor necrosis factor-alpha production and oxidative stress in the failing hearts of patients with dilated cardiomyopathy. J Am Coll Cardiol 2001; 37: 2086-92.
20. Dandel M, Weng Y, Siniawski H, Potapov E, Lehmkuhl HB, Hetzer R. Long-term results in patients with idiopathic dilated cardiomyopathy after weaning from left ventricular assist devices. Circulation 2005; 112: I37-45.
21. Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003; 362: 7-13.
22. Di Lenarda A, Remme WJ, Charlesworth A, et al. Exchange of beta-blockers in heart failure patients. Experiences from the poststudy phase of COMET (the Carvedilol or Metoprolol European Trail) Eur J Heart Fail 2005; 7: 640-9.
23. Watanabe K, Ohta Y, Nakazawa M, et al. Low dose carvedilol inhibits progression of heart failure in rats with dilated cardiomyopathy. Br J Pharmacol 2000; 130: 1489-95.
24. Dalla Libera L, Ravara B, Gobbo V, et al. Skeletal muscle myofibrillar protein oxidation in heart failure and the protective effect of Carvedilol. J Mol Cell Cardiol 2005; 38: 803-7.
25. Krämer C, Sunkomat J, Witte J, et al. Angiotensin II receptor-independent antiinflammatory and antiaggregatory properties of losartan: role of the active metabolite EXP3179. Circ Res 2002; 90: 770-6.
26. Watanabe T, Suzuki J, Yamawaki H, Sharma VK, Sheu SS, Berk BC. Losartan metabolite EXP3179 activates Akt and endothelial nitric oxide synthase via vascular endothelial growth factor receptor-2 in endothelial cells: angiotensin II type 1 receptor-independent effects of EXP3179. Circulation 2005; 112: 1798-805.
27. Kodama M, Zhang S, Hanawa H, et al. Effects of 15-deoxysperqualin on experimental autoimmune giant cell myocarditis of the rat. Circulation 1995; 91: 1116-22.
28. Sheu JJ, Chang LT, Chiang CH, et al. Impact of diabetes on cardiomyocyte apoptosis and connexin43 gap junction integrity: role of pharmacological modulation. Int Heart J 2007; 48: 233-45.
29. Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 2004; 109: 2054-7.
30. Chang LT, Sun CK, Chiang CH, Wu CJ, Chua S, Yip HK. Impact of simvastatin and losartan on antiinflammatory effect: in vitro study. J Cardiovasc Pharmacol 2007; 49: 20-6.
31. Woodley SL, McMillan M, Shelby J, et al. Myocyte injury and contraction abnormalities produced by cytotoxic T lymphocytes. Circulation 1991; 83: 1410-8.